← 返回

携带 siRNA-PD-L1 的减毒沙门氏菌联合放疗通过 T 细胞介导的免疫增强诱导 HCC 肿瘤消退

英文原题:Attenuated Salmonella carrying siRNA-PD-L1 and radiation combinatorial therapy induces tumor regression on HCC through T cell-mediated immuno-enhancement.

查看英文原题

Attenuated Salmonella carrying siRNA-PD-L1 and radiation combinatorial therapy induces tumor regression on HCC through T cell-mediated immuno-enhancement.

PubMed 2023/08/28(内容时间) Cell Death Discov Q1 · IF 10.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

肝细胞癌(HCC)是侵袭性肝癌中最常见的类型,占肝癌诊断和死亡的大多数。尽管近年来HCC治疗取得了进展,但它仍然是最致命的癌症之一。放射治疗(RT)是用于治疗不可切除或医学上无法手术的HCC的局部区域治疗方式之一。

然而,放射抵抗构成了重大挑战。已有研究表明,RT诱导肿瘤细胞上程序性死亡配体1(PD-L1)的上调,这可能影响对基于PD-1的免疫治疗的反应,为将PD-1/PD-L1抑制剂与放射治疗联合提供了依据。

在此,我们利用减毒沙门氏菌作为载体,探讨携带siRNA-PD-L1的减毒沙门氏菌是否能有效增强放射治疗对荷HCC小鼠的抗肿瘤效果。

我们的结果表明,siRNA-PD-L1与放射治疗的联合通过抑制放射治疗诱导的PD-L1表达,产生了协同抗肿瘤效应。机制研究提示,联合治疗显著抑制了肿瘤细胞增殖,促进了细胞凋亡,并刺激了肿瘤组织中的免疫细胞浸润和活化。

此外,联合治疗提高了荷瘤小鼠脾脏中CD4 + T、CD8 + T和NK细胞的比例。本研究为HCC治疗提出了一种新的治疗策略,尤其适用于RT抵抗的患者。

展开英文摘要原文

Hepatocellular carcinoma (HCC), the most prevalent type of aggressive liver cancer, accounts for the majority of liver cancer diagnoses and fatalities. Despite recent advancements in HCC treatment, it remains one of the deadliest cancers. Radiation therapy (RT) is among the locoregional therapy modalities employed to treat unresectable or medically inoperable HCC.

However, radioresistance poses a significant challenge. It has been demonstrated that RT induced the upregulation of programmed death ligand 1 (PD-L1) on tumor cells, which may affect response to PD-1-based immunotherapy, providing a rationale for combining PD-1/PD-L1 inhibitors with radiation.

Here, we utilized attenuated Salmonella as a carrier to explore whether attenuated Salmonella carrying siRNA-PD-L1 could effectively enhance the antitumor effect of radiotherapy on HCC-bearing mice.

Our results showed that a combination of siRNA-PD-L1 and radiotherapy had a synergistic antitumor effect by inhibiting the expression of PD-L1 induced by radiation therapy. Mechanistic insights indicated that the combination treatment significantly suppressed tumor cell proliferation, promoted cell apoptosis, and stimulated immune cell infiltration and activation in tumor tissues.

Additionally, the combination treatment increased the ratios of CD4 + T, CD8 + T, and NK cells from the spleen in tumor-bearing mice.

This study presents a novel therapeutic strategy for HCC treatment, especially for patients with RT resistance.

论文信息

作者
Jia H、Wei P、Zhou S、Hu Y、Zhang C、Liang L、Li B、Gan Z
第一作者单位
Department of Oncology, The Third Affiliated Hospital of Xinxiang Medical University, 453000, Xinxiang, Henan, P. R. China.China
通讯作者单位
Department of Oncology, The Third Affiliated Hospital of Xinxiang Medical University, 453000, Xinxiang, Henan, P. R. China. zhaotiesuo1106@163.com.China
期刊
Cell death discovery2023 Aug 28
原文标识
PubMed 37640735 · DOI 10.1038/s41420-023-01603-x